Skip to main content
Fig. 2 | Cell & Bioscience

Fig. 2

From: BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation

Fig. 2

ABT-263 significantly enhances the anticancer effects apigenin in tumor cells containing activating EGFR mutation. H1975, HCC827 and H1650 cells were incubated with the indicated dosages of apigenin (Apg) or ABT-263 (ABT), alone or the combination (comb) for 1 day (a), or were treated with Apg (15 µM), ABT (2 µM) or their combination for up to 3 days (b), and the cell viability were detected by MTT assay. c H1975 and HCC827 cells were seeded in 24-well plates and treated with the indicated dosages of Apg or ABT, alone or the comb for 14 days. The adherent cells were then stained with crystal violet for the colony formation assay. d Tumor cells with different genetic background and immortalized human Pulmonary Artery Smooth Muscle cells were treated with the indicated drugs for 1 day. The cell viability rates were examined by MTT and the Coefficient of Drug Interaction (CDI) values were calculated. e, f Cells were treated with Apg (15 µM) and ABT (2 µM), alone or in combination for 1 day. Apoptotic cell death was analyzed (e), and cleaved PARP and cleaved caspase 3 were examined by Western blotting. β-Tubulin was detected as an endogenous loading control (f). Data represent mean ± SD (n = 3). **p < 0.01 vs single compound treatment group. g Bax was knocked down by shRNA in H1975 and HCC827 cells, and the cells were treated with drugs as described in e, followed by cell apoptosis analysis (left) and Western blotting analysis of Bax and cleaved caspase 3 (right). The data represents mean ± SD (n = 3). *p < 0.05, and **p < 0.01 vs ctrl-sh group

Back to article page